Study identifier:D0816R00013
ClinicalTrials.gov identifier:NCT03229122
EudraCT identifier:N/A
CTIS identifier:N/A
Japan CHARLOTTE: Characterizing the cross-sectional approach to Ovarian cancer: Genetic testing of BRCA
ovarian cancer
N/A
No
-
Female
446
Observational
20 Years - 130 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: Open Label
Primary Purpose: -
Verified 01 Jun 2019 by AstraZeneca
AstraZeneca
-
The multi-centered, cross-sectional investigations shall be conducted in this study with the objective of identifying the ownership ratio of gBRCAm on the newly diagnosed patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer in Japan.
This multi-centered, cooperative and epidemiological observation study is so designed to investigate the ownership ratio of gBRCAm in the newly diagnosed patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer because such a ratio has not yet been adequately clarified in Japan. The newly diagnosed eligible patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer shall be asked to participate in this study in order of diagnosis. After obtaining their consents by the written informed consent following appropriate explanation, investigations about the demographic information including the cancer family history shall be performed. Subsequently, blood is collected for investigation about gBRCAm. In addition, histological classification shall be conducted based on the resected tumor tissues.
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.